enoxaparin, Lovenox

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

Deep Vein Thrombosis (DVT)

GENERIC NAME: enoxaparin


DRUG CLASS AND MECHANISM: Enoxaparin is a low molecular weight heparin (LMWH) that is used to prevent blood clots. It is produced by chemically breaking heparin into smaller-sized molecules. Unlike heparin, the effect of enoxaparin does not need to be monitored with blood tests. Like heparin, enoxaparin prevents blood clots from forming by blocking the action of two of the 12 clot-promoting proteins in blood (factors X and II) whose action is necessary for blood to clot. Enoxaparin is used to treat or prevent blood clots and their complications (deep vein thrombosis or DVT and pulmonary embolism or PE). Deep vein thrombosis is the formation of blood clots in veins deep in a muscle, most often in the legs deep vein thrombosis may lead to pulmonary embolism, a condition in which a piece of the clot (the embolus) breaks loose and travels through the veins to the lung. In the lung the clot blocks an artery and prevents the part of the lung that is supplied by the artery from working normally. If the artery that is blocked is a large artery, the embolus can cause sudden death. Thrombosis and embolism are responsible for 300,000 to 600,000 hospitalizations each year, and pulmonary embolism causes as many as 200,000 deaths each year in the U.S. Patients undergoing hip replacement and other major surgery are at increased risk of deep vein thrombosis and pulmonary embolism. The FDA approved enoxaparin in 1993.

PRESCRIBED FOR: Enoxaparin is used for preventing deep vein thrombosis after abdominal, hip replacement, or knee replacement surgeries, and in patients with reduced mobility due to illness. It is used both in and out of the hospital for treating deep vein thrombosis and pulmonary embolism. Enoxaparin also is used for preventing a second heart attack and related complications after a heart attack and for preventing blood clots in arterial stents.

SIDE EFFECTS: Common side effect associated with enoxaparin are:

Other important side effects are:

Medically Reviewed by a Doctor on 8/5/2015

Quick GuideDeep Vein Thrombosis (DVT): Symptoms, Treatment & Prevention

Deep Vein Thrombosis (DVT): Symptoms, Treatment & Prevention
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: enoxaparin on RxList
RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Heart Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors